Patent 12077755 was granted and assigned to University of Massachusetts on September, 2024 by the United States Patent and Trademark Office.
Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.